Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Lindsay Claxton"'
Autor:
Lindsay Claxton, Mark Simmonds, Lucy Beresford, Richard Cubbon, Mark Dayer, Stephen S Gottlieb, Nick Hartshorne-Evans, Bruce Kilroy, Alexis Llewellyn, Claire Rothery, Sahar Sharif, Jayne F Tierney, Klaus K Witte, Kath Wright, Lesley A Stewart
Publikováno v:
Health Technology Assessment, Vol 26, Iss 4 (2022)
Background: Chronic heart failure is a debilitating condition that accounts for an annual NHS spend of £2.3B. Low levels of endogenous coenzyme Q10 may exacerbate chronic heart failure. Coenzyme Q10 supplements might improve symptoms and slow progre
Externí odkaz:
https://doaj.org/article/b151c5176c8c45e09fa4005ddb878ab4
Autor:
Ros Wade, Sahar Sharif-Hurst, Melissa Harden, Matthew Walton, Lindsay Claxton, Robert Hodgson, Alison Eastwood
Publikováno v:
Systematic Reviews, Vol 9, Iss 1, Pp 1-8 (2020)
Abstract Background Systematic reviews of medical devices are particularly challenging as the quality of evidence tends to be more limited than evidence on pharmaceutical products. This article describes the methods used to identify, select and criti
Externí odkaz:
https://doaj.org/article/31b9ca0dc61c4ca9b03456d1f3f43ac5
Autor:
Peter Murphy, David Glynn, Sofia Dias, Robert Hodgson, Lindsay Claxton, Lucy Beresford, Katy Cooper, Paul Tappenden, Kate Ennis, Alessandro Grosso, Kath Wright, Anna Cantrell, Matt Stevenson, Stephen Palmer
Publikováno v:
Health Technology Assessment, Vol 25, Iss 76 (2021)
Background: The first histology-independent marketing authorisation in Europe was granted in 2019. This was the first time that a cancer treatment was approved based on a common biomarker rather than the location in the body at which the tumour origi
Externí odkaz:
https://doaj.org/article/7a03693ef323487dbae4b4c496fd19ab
Publikováno v:
Health Services and Delivery Research (2020)
Background: Advance care planning (ACP) can be defined as a voluntary process of discussion about future care between an individual and their care providers, irrespective of discipline. An ACP discussion might include an individual’s concerns and w
Externí odkaz:
https://doaj.org/article/67625e3155734742ab3ae6060f4c6201
Autor:
Matthew Walton, Ros Wade, Lindsay Claxton, Sahar Sharif-Hurst, Melissa Harden, Jai Patel, Ian Rowe, Robert Hodgson, Alison Eastwood
Publikováno v:
Health Technology Assessment, Vol 24, Iss 48 (2020)
Background: Hepatocellular carcinoma is the most common type of primary liver cancer. Treatment choice is dependent on underlying liver dysfunction and cancer stage. Treatment options include conventional transarterial therapies for patients with int
Externí odkaz:
https://doaj.org/article/4480955920e843dea032608fc8f9f0b3
Autor:
Lindsay Claxton, Matthew Walton, Sahar Sharif-Hurst, Ros Wade, Alison Eastwood, Robert Hodgson
Publikováno v:
Value in Health. 25:787-795
To assess the cost-effectiveness of selective internal radiation therapy (SIRT) compared with sorafenib for the treatment of patients with advanced hepatocellular carcinoma in the United Kingdom, including a selected subgroup of patients who have bee
Autor:
Stephen Palmer, Lindsay Claxton, Lucy Beresford, Peter James Murphy, David Glynn, Alexis Llewellyn, Robert Hodgson, Sofia Dias, Matthew Walton
Publikováno v:
Medical Decision Making
Background The National Institute for Health and Care Excellence and a number of international health technology assessment agencies have recently undertaken appraisals of histology-independent technologies (HITs). A strong and untested assumption in
Autor:
Chao Hsiun Tang, Ping Ning Hsu, Satish Valluri, Der-Yuan Chen, Lindsay Claxton, Robert A. Gerber
Publikováno v:
Journal of Medical Economics. 22:777-787
Aims: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis investigated the cost-effectiveness of the second-line treatment with tofacitinib, ...
Publikováno v:
PharmacoEconomics Open
Background Escalating demands upon the National Institute for Health and Care Excellence’s (NICE’s) Single Technology Appraisal (STA) programme require a 2.5-times increase upon 2015 capacity by 2020. This additional strain on committee resources
Publikováno v:
PharmacoEconomics. 37:645-654
The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ceritinib (Zykadia®, Novartis) to submit evidence on the clinical and cost effectiveness of the drug, as a first-line treatment for adults with anapla